» Articles » PMID: 25763579

Investigation of Occult Hepatitis B Virus Infection in Anti-hbc Positive Patients from a Liver Clinic

Overview
Journal PLoS One
Date 2015 Mar 13
PMID 25763579
Citations 7
Authors
Affiliations
Soon will be listed here.
Abstract

Occult hepatitis B infection (OBI) is manifested by presence of very low levels (<200IU/mL) of Hepatitis B viral DNA (HBV DNA) in the blood and the liver while exhibiting undetectable HBV surface antigen (HBsAg). The molecular mechanisms underlying this occurrence are still not completely understood. This study investigated the prevalence of OBI in a high-risk Australian population and compared the HBV S gene sequences of our cohort with reference sequences. Serum from HBV DNA positive, HBsAg negative, and hepatitis B core antibody (anti-HBc) positive patients (study cohort) were obtained from samples tested at SEALS Serology Laboratory using the Abbott Architect, as part of screening and diagnostic testing. From a total of 228,108 samples reviewed, 1,451 patients were tested for all three OBI markers. Only 10 patients (0.69%) out of the 1,451 patients were found to fit the selection criteria for OBI. Sequence analysis of the HBV S gene from 5 suspected OBI infected patients showed increased sequence variability in the 'a' epitope of the major hydrophilic region compared to reference sequences. In addition, a total of eight consistent nucleotide substitutions resulting in seven amino acid changes were observed, and three patients had truncated S gene sequence. These mutations appeared to be stable and may result in alterations in HBsAg conformation. These may negatively impact the affinity of hepatitis B surface antibody (anti-HBs) and may explain the false negative results in serological HBV diagnosis. These changes may also enable the virus to persist in the liver by evading immune surveillance. Further studies on a bigger cohort are required to determine whether these amino acid variations have been acquired in the process of immune escape and serve as markers of OBI.

Citing Articles

Low Risk of Occult Hepatitis B Infection among Vietnamese Blood Donors.

Tung T, Schmid J, Nghia V, Chi Cao L, Linh L, Rungsung I Pathogens. 2022; 11(12).

PMID: 36558858 PMC: 9786887. DOI: 10.3390/pathogens11121524.


Prevalence of occult hepatitis B virus infection among patients receiving haemodialysis in Sana'a city.

Al-Masoodi B, Reem A, Bahaj S, Al-Haimi R, Al-Shamahy H, Abuasba N IJID Reg. 2022; 5:141-145.

PMID: 36341041 PMC: 9634008. DOI: 10.1016/j.ijregi.2022.09.004.


Molecular investigation of occult hepatitis B virus infection in a reference center in Northern Brazil.

Araujo S, Malheiros A, Sarmento V, Nunes H, Freitas P Braz J Infect Dis. 2022; 26(3):102367.

PMID: 35598631 PMC: 9387453. DOI: 10.1016/j.bjid.2022.102367.


Prevalence of Occult Hepatitis B Virus Infection in Hemodialysis Patients Using Nested PCR.

Samadi E, Mirshahabi H, Motamed N, Sadeghi H Rep Biochem Mol Biol. 2020; 9(1):82-88.

PMID: 32821755 PMC: 7424425. DOI: 10.29252/rbmb.9.1.82.


Antiviral effects of hepatitis B virus S gene-specific anti-gene locked nucleic acid in transgenic mice.

Xiao S, Xu G, Wei W, Peng B, Deng Y World J Clin Cases. 2018; 6(8):183-191.

PMID: 30148146 PMC: 6107528. DOI: 10.12998/wjcc.v6.i8.183.


References
1.
Pollicino T, Cacciola I, Saffioti F, Raimondo G . Hepatitis B virus PreS/S gene variants: pathobiology and clinical implications. J Hepatol. 2014; 61(2):408-17. DOI: 10.1016/j.jhep.2014.04.041. View

2.
Schories M, Peters T, Rasenack J . Isolation, characterization and biological significance of hepatitis B virus mutants from serum of a patient with immunologically negative HBV infection. J Hepatol. 2000; 33(5):799-811. DOI: 10.1016/s0168-8278(00)80313-x. View

3.
Katsoulidou A, Paraskevis D, Magiorkinis E, Moschidis Z, Haida C, Hatzitheodorou E . Molecular characterization of occult hepatitis B cases in Greek blood donors. J Med Virol. 2009; 81(5):815-25. DOI: 10.1002/jmv.21499. View

4.
Chemin I, Trepo C . Clinical impact of occult HBV infections. J Clin Virol. 2006; 34 Suppl 1:S15-21. DOI: 10.1016/s1386-6532(05)80005-8. View

5.
Orito E, Mizokami M, Sakugawa H, Michitaka K, Ishikawa K, Ichida T . A case-control study for clinical and molecular biological differences between hepatitis B viruses of genotypes B and C. Japan HBV Genotype Research Group. Hepatology. 2000; 33(1):218-23. DOI: 10.1053/jhep.2001.20532. View